Home Applications 207145 Application 207145
Type NDA
Sponsor US WORLDMEDS LLC Application Products# Product, Drug, Ingredient table Product Drug Ingredient Form Strength Reference drug Reference standard 001 XADAGO SAFINAMIDE MESYLATE TABLET;ORAL 50MG Yes No 002 XADAGO SAFINAMIDE MESYLATE TABLET;ORAL 100MG Yes Yes
Source provenance: Browse the complete Orange Book source catalog · source snapshot 44 .
Orange Book products# Current product rows page 1 of 1 · 2 matching rows.
Application-product, Trade name, Ingredient table Application-product Trade name Ingredient Strength Dosage form / route TE codes RLD / RS Approval date N207145-001 XADAGO SAFINAMIDE MESYLATE EQ 50MG BASE TABLET / ORAL AB RLD 2017-03-21 N207145-002 XADAGO SAFINAMIDE MESYLATE EQ 100MG BASE TABLET / ORAL AB RLD, RS 2017-03-21
Therapeutic equivalence codes# Current TE-code rows page 1 of 1 · 2 matching rows.
Orange Book patents# Current patent rows page 1 of 1 · 6 matching rows.
Application-product, Patent, Expiration table Application-product Patent Expiration Use code Coverage / status Submission date N207145-001 8278485 2027-06-08 U-1993 Drug substance 2017-04-20 N207145-001 8076515 2028-12-10 U-1993 Drug substance, Drug product 2017-04-20 N207145-001 8283380 2031-03-21 U-1993 2017-04-20 N207145-002 8278485 2027-06-08 U-1993 Drug substance 2017-04-20 N207145-002 8076515 2028-12-10 U-1993 Drug substance, Drug product 2017-04-20 N207145-002 8283380 2031-03-21 U-1993 2017-04-20
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Product history page 2 of 3 · 88 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2019-12-13 00:20 UTC 2019-12 N207145-001 XADAGO 50MG TABLET / ORAL RLD 2017-03-21 74a2ff9319b5…2019-12-13 00:20 UTC 2019-12 N207145-002 XADAGO 100MG TABLET / ORAL RLD, RS 2017-03-21 74a2ff9319b5…2022-03-09 01:35 UTC 2022-03 N207145-001 XADAGO EQ 50MG BASE TABLET / ORAL RLD 2017-03-21 bb7c543d1eb4…2022-03-09 01:35 UTC 2022-03 N207145-002 XADAGO EQ 100MG BASE TABLET / ORAL RLD, RS 2017-03-21 bb7c543d1eb4…2021-12-28 21:50 UTC 2021-12 N207145-001 XADAGO EQ 50MG BASE TABLET / ORAL RLD 2017-03-21 782e0a99824c…2021-12-28 21:50 UTC 2021-12 N207145-002 XADAGO EQ 100MG BASE TABLET / ORAL RLD, RS 2017-03-21 782e0a99824c…2021-05-05 16:15 UTC · 3 captures of this ZIP 2021-05 N207145-001 XADAGO 50MG TABLET / ORAL RLD 2017-03-21 87673890dc5c…2021-05-05 16:15 UTC · 3 captures of this ZIP 2021-05 N207145-002 XADAGO 100MG TABLET / ORAL RLD, RS 2017-03-21 87673890dc5c…2021-03-12 10:30 UTC 2021-03 N207145-001 XADAGO 50MG TABLET / ORAL RLD 2017-03-21 5aa47cf7b7d7…2021-03-12 10:30 UTC 2021-03 N207145-002 XADAGO 100MG TABLET / ORAL RLD, RS 2017-03-21 5aa47cf7b7d7…2020-12-22 03:56 UTC 2020-12 N207145-001 XADAGO 50MG TABLET / ORAL RLD 2017-03-21 8869cabd3fbd…2020-12-22 03:56 UTC 2020-12 N207145-002 XADAGO 100MG TABLET / ORAL RLD, RS 2017-03-21 8869cabd3fbd…2020-11-12 02:37 UTC 2020-11 N207145-001 XADAGO 50MG TABLET / ORAL RLD 2017-03-21 c0c555d07b60…2020-11-12 02:37 UTC 2020-11 N207145-002 XADAGO 100MG TABLET / ORAL RLD, RS 2017-03-21 c0c555d07b60…2019-12-14 00:12 UTC 2019-12 N207145-001 XADAGO 50MG TABLET / ORAL RLD 2017-03-21 3f01610625f2…2019-12-14 00:12 UTC 2019-12 N207145-002 XADAGO 100MG TABLET / ORAL RLD, RS 2017-03-21 3f01610625f2…2019-09-15 20:21 UTC 2019-09 N207145-001 XADAGO 50MG TABLET / ORAL RLD 2017-03-21 b00525d2431f…2019-09-15 20:21 UTC 2019-09 N207145-002 XADAGO 100MG TABLET / ORAL RLD, RS 2017-03-21 b00525d2431f…2019-07-19 19:46 UTC 2019-07 N207145-001 XADAGO 50MG TABLET / ORAL RLD 2017-03-21 ea99ee380514…2019-07-19 19:46 UTC 2019-07 N207145-002 XADAGO 100MG TABLET / ORAL RLD, RS 2017-03-21 ea99ee380514…2024-03-16 18:09 UTC · 4 captures of this ZIP 2024-03 N207145-001 XADAGO EQ 50MG BASE TABLET / ORAL RLD 2017-03-21 6a51e52b5d6a…2024-03-16 18:09 UTC · 4 captures of this ZIP 2024-03 N207145-002 XADAGO EQ 100MG BASE TABLET / ORAL RLD, RS 2017-03-21 6a51e52b5d6a…2024-02-18 07:12 UTC 2024-02 N207145-001 XADAGO EQ 50MG BASE TABLET / ORAL RLD 2017-03-21 1c564ffb4f44…2024-02-18 07:12 UTC 2024-02 N207145-002 XADAGO EQ 100MG BASE TABLET / ORAL RLD, RS 2017-03-21 1c564ffb4f44…2023-12-20 04:57 UTC 2023-12 N207145-001 XADAGO EQ 50MG BASE TABLET / ORAL RLD 2017-03-21 ea1830bbd6c7…2023-12-20 04:57 UTC 2023-12 N207145-002 XADAGO EQ 100MG BASE TABLET / ORAL RLD, RS 2017-03-21 ea1830bbd6c7…2023-11-28 05:40 UTC · 2 captures of this ZIP 2023-11 N207145-001 XADAGO EQ 50MG BASE TABLET / ORAL RLD 2017-03-21 a72a2bbeb626…2023-11-28 05:40 UTC · 2 captures of this ZIP 2023-11 N207145-002 XADAGO EQ 100MG BASE TABLET / ORAL RLD, RS 2017-03-21 a72a2bbeb626…2023-10-25 00:34 UTC · 2 captures of this ZIP 2023-10 N207145-001 XADAGO EQ 50MG BASE TABLET / ORAL RLD 2017-03-21 9b2671bbb829…2023-10-25 00:34 UTC · 2 captures of this ZIP 2023-10 N207145-002 XADAGO EQ 100MG BASE TABLET / ORAL RLD, RS 2017-03-21 9b2671bbb829…2023-07-15 15:27 UTC · 2 captures of this ZIP 2023-07 N207145-001 XADAGO EQ 50MG BASE TABLET / ORAL RLD 2017-03-21 a67488948f0b…2023-07-15 15:27 UTC · 2 captures of this ZIP 2023-07 N207145-002 XADAGO EQ 100MG BASE TABLET / ORAL RLD, RS 2017-03-21 a67488948f0b…2023-06-13 01:57 UTC · 3 captures of this ZIP 2023-06 N207145-001 XADAGO EQ 50MG BASE TABLET / ORAL RLD 2017-03-21 3f0d92c62455…2023-06-13 01:57 UTC · 3 captures of this ZIP 2023-06 N207145-002 XADAGO EQ 100MG BASE TABLET / ORAL RLD, RS 2017-03-21 3f0d92c62455…2023-05-13 08:27 UTC 2023-05 N207145-001 XADAGO EQ 50MG BASE TABLET / ORAL RLD 2017-03-21 053a50430f4f…2023-05-13 08:27 UTC 2023-05 N207145-002 XADAGO EQ 100MG BASE TABLET / ORAL RLD, RS 2017-03-21 053a50430f4f…2023-01-26 05:58 UTC 2023-01 N207145-001 XADAGO EQ 50MG BASE TABLET / ORAL RLD 2017-03-21 3bdfa0b2c4d7…2023-01-26 05:58 UTC 2023-01 N207145-002 XADAGO EQ 100MG BASE TABLET / ORAL RLD, RS 2017-03-21 3bdfa0b2c4d7…2022-11-12 20:34 UTC · 5 captures of this ZIP 2022-11 N207145-001 XADAGO EQ 50MG BASE TABLET / ORAL RLD 2017-03-21 3a93d1ddd44b…2022-11-12 20:34 UTC · 5 captures of this ZIP 2022-11 N207145-002 XADAGO EQ 100MG BASE TABLET / ORAL RLD, RS 2017-03-21 3a93d1ddd44b…
Observed Orange Book normalized TE history# Observed Orange Book patent history# Patent history page 1 of 7 · 264 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Patent Expiration Use code Coverage / status Submission date Source SHA-256 2026-10-15 13:18:30 2026-09 N207145-001 8278485 2027-06-08 U-1993 Drug substance 2017-04-20 c2088c7a36db…2026-10-15 13:18:30 2026-09 N207145-001 8076515 2028-12-10 U-1993 Drug substance, Drug product 2017-04-20 c2088c7a36db…2026-10-15 13:18:30 2026-09 N207145-001 8283380 2031-03-21 U-1993 2017-04-20 c2088c7a36db…2026-10-15 13:18:30 2026-09 N207145-002 8278485 2027-06-08 U-1993 Drug substance 2017-04-20 c2088c7a36db…2026-10-15 13:18:30 2026-09 N207145-002 8076515 2028-12-10 U-1993 Drug substance, Drug product 2017-04-20 c2088c7a36db…2026-10-15 13:18:30 2026-09 N207145-002 8283380 2031-03-21 U-1993 2017-04-20 c2088c7a36db…2026-09-14 22:38:34 2026-08 N207145-001 8278485 2027-06-08 U-1993 Drug substance 2017-04-20 84e616aacf4f…2026-09-14 22:38:34 2026-08 N207145-001 8076515 2028-12-10 U-1993 Drug substance, Drug product 2017-04-20 84e616aacf4f…2026-09-14 22:38:34 2026-08 N207145-001 8283380 2031-03-21 U-1993 2017-04-20 84e616aacf4f…2026-09-14 22:38:34 2026-08 N207145-002 8278485 2027-06-08 U-1993 Drug substance 2017-04-20 84e616aacf4f…2026-09-14 22:38:34 2026-08 N207145-002 8076515 2028-12-10 U-1993 Drug substance, Drug product 2017-04-20 84e616aacf4f…2026-09-14 22:38:34 2026-08 N207145-002 8283380 2031-03-21 U-1993 2017-04-20 84e616aacf4f…2026-08-18 06:07:40 2026-07 N207145-001 8278485 2027-06-08 U-1993 Drug substance 2017-04-20 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N207145-001 8076515 2028-12-10 U-1993 Drug substance, Drug product 2017-04-20 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N207145-001 8283380 2031-03-21 U-1993 2017-04-20 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N207145-002 8278485 2027-06-08 U-1993 Drug substance 2017-04-20 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N207145-002 8076515 2028-12-10 U-1993 Drug substance, Drug product 2017-04-20 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N207145-002 8283380 2031-03-21 U-1993 2017-04-20 caaa826d4ba7…2026-02-19 14:30 UTC 2026-02 N207145-001 8278485 2027-06-08 U-1993 Drug substance 2017-04-20 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N207145-001 8076515 2028-12-10 U-1993 Drug substance, Drug product 2017-04-20 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N207145-001 8283380 2031-03-21 U-1993 2017-04-20 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N207145-002 8278485 2027-06-08 U-1993 Drug substance 2017-04-20 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N207145-002 8076515 2028-12-10 U-1993 Drug substance, Drug product 2017-04-20 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N207145-002 8283380 2031-03-21 U-1993 2017-04-20 011fe1cb6892…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N207145-001 8278485 2027-06-08 U-1993 Drug substance 2017-04-20 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N207145-001 8076515 2028-12-10 U-1993 Drug substance, Drug product 2017-04-20 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N207145-001 8283380 2031-03-21 U-1993 2017-04-20 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N207145-002 8278485 2027-06-08 U-1993 Drug substance 2017-04-20 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N207145-002 8076515 2028-12-10 U-1993 Drug substance, Drug product 2017-04-20 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N207145-002 8283380 2031-03-21 U-1993 2017-04-20 31067a03dcf5…2025-08-23 18:47 UTC 2025-08 N207145-001 8278485 2027-06-08 U-1993 Drug substance 2017-04-20 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N207145-001 8076515 2028-12-10 U-1993 Drug substance, Drug product 2017-04-20 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N207145-001 8283380 2031-03-21 U-1993 2017-04-20 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N207145-002 8278485 2027-06-08 U-1993 Drug substance 2017-04-20 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N207145-002 8076515 2028-12-10 U-1993 Drug substance, Drug product 2017-04-20 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N207145-002 8283380 2031-03-21 U-1993 2017-04-20 6a471c1ec25d…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N207145-001 8278485 2027-06-08 U-1993 Drug substance 2017-04-20 fd3edfee7708…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N207145-001 8076515 2028-12-10 U-1993 Drug substance, Drug product 2017-04-20 fd3edfee7708…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N207145-001 8283380 2031-03-21 U-1993 2017-04-20 fd3edfee7708…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N207145-002 8278485 2027-06-08 U-1993 Drug substance 2017-04-20 fd3edfee7708…
Observed Orange Book exclusivity history# Reported adverse events (FAERS/openFDA)# Adverse event summaries are temporarily unavailable. Other product information remains available.
NDC Listings For This Application# NDC listings for this application page 1 of 1 · 18 matching rows.
NDC, Name, Nonproprietary name table NDC Name Nonproprietary name Labeler Marketing category Status 27505-110 Xadago safinamide mesylate US WorldMeds, LLC NDA Current 27505-110 Xadago safinamide mesylate US WorldMeds, LLC NDA Current 27505-110 Xadago safinamide mesylate MDD US Operations, LLC NDA Current 27505-110 Xadago safinamide mesylate US WorldMeds, LLC NDA Current 27505-110 Xadago safinamide mesylate MDD US Operations, LLC NDA Current 27505-110 Xadago safinamide mesylate MDD US Operations LLC, a subsidiary of Supernus Pharmaceuticals, Inc. NDA Current 27505-110 Xadago safinamide mesylate MDD US Operations LLC, a subsidiary of Supernus Pharmaceuticals, Inc. NDA Current 27505-110 Xadago safinamide mesylate MDD US Operations LLC, a subsidiary of Supernus Pharmaceuticals, Inc. NDA Current 27505-110 Xadago safinamide mesylate US WorldMeds, LLC NDA Current 27505-111 Xadago safinamide mesylate US WorldMeds, LLC NDA Current 27505-111 Xadago safinamide mesylate US WorldMeds, LLC NDA Current 27505-111 Xadago safinamide mesylate MDD US Operations, LLC NDA Current 27505-111 Xadago safinamide mesylate US WorldMeds, LLC NDA Current 27505-111 Xadago safinamide mesylate MDD US Operations, LLC NDA Current 27505-111 Xadago safinamide mesylate MDD US Operations LLC, a subsidiary of Supernus Pharmaceuticals, Inc. NDA Current 27505-111 Xadago safinamide mesylate MDD US Operations LLC, a subsidiary of Supernus Pharmaceuticals, Inc. NDA Current 27505-111 Xadago safinamide mesylate MDD US Operations LLC, a subsidiary of Supernus Pharmaceuticals, Inc. NDA Current 27505-111 Xadago safinamide mesylate US WorldMeds, LLC NDA Current
Documents# Document, Submission type, Date table Document Submission type Date 68325 SUPPL 2021-08-10 68316 SUPPL 2021-08-09 61100 SUPPL 2019-11-29 61081 SUPPL 2019-11-27 48775 SUPPL 2017-06-20 48756 SUPPL 2017-06-19 48180 ORIG 2017-05-01 47730 ORIG 2017-03-28 47630 ORIG 2017-03-22